WYATT CLARK: Open Payments
NPI 1598462533 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,550 in 49 payments from 9 companies in 2025. Trend: 2023 $1,351 · 2024 $2,467 · 2025 $1,550
Food & beverage: $1,550
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $363 |
| Alkermes, Inc. | 6 | $341 |
| ABBVIE INC. | 13 | $334 |
| E.R. Squibb & Sons, L.L.C. | 5 | $138 |
| Janssen Pharmaceuticals, Inc | 2 | $117 |
| Vanda Pharmaceuticals Inc. | 3 | $99 |
| Otsuka America Pharmaceutical, Inc. | 4 | $92 |
| Neurocrine BioSciences, Inc. | 2 | $36 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
Products named: CAPLYTA, VRAYLAR, ARISTADA, COBENFY, LYBALVI, INVEGA SUSTENNA, FANAPT, REXULTI.
Industry payments across NV — which companies pay providers there.
